Ranbaxy
wanted the order to prevent competitors Dr. Reddy’s Laboratories Ltd and the US
unit of Dublin-based Endo International from moving ahead with marketing their
generic versions of the compounds while its complaint was heard. Photo: Pradeep
Gaur/Mint Washington: Ranbaxy Laboratories Ltd lost a bid for a temporary court
order to block rivals’ generic versions of the heartburn pill Nexium and the
antiviral drug Valcyte.
Ranbaxy sought the order in a lawsuit against the US
Food and Drug Administration (FDA) over the agency’s revocation of tentative
approval for the company to make its own generic versions of the drugs. The FDA
revocation wrongfully punishes Ranbaxy for manufacturing deficiencies found at
two Indian facilities in 2006 and 2008, blocking “hundreds of millions of
dollars in anticipated revenue,” the company said in aRanbaxy wanted the order
to prevent competitors Dr. Reddy’s Laboratories Ltd and the US unit of
Dublin-based Endo International from moving ahead with marketing their generic
versions of the compounds while its complaint was heard. Photo:
Pradeep
Gaur/Mint Washington: Ranbaxy Laboratories Ltd lost a bid for a temporary court
order to block rivals’ generic versions of the heartburn pill Nexium and the
antiviral drug Valcyte. Ranbaxy sought the order in a lawsuit against the US
Food and Drug Administration (FDA) over the agency’s revocation of tentative
approval for the company to make its own generic versions of the drugs. The FDA
revocation wrongfully punishes Ranbaxy for manufacturing deficiencies found at
two Indian facilities in 2006 and 2008, blocking “hundreds of millions of
dollars in anticipated revenue,” the company said in a complaint filed on 14
November in federal court in Washington.
Ranbaxy, based in Gurgaon, wanted the
order to prevent competitors Dr. Reddy’s Laboratories Ltd and the US unit of
Dublin-based Endo International Plc from moving ahead with marketing their
generic versions of the compounds while its complaint was heard. US district
judge Beryl Howell on Thursday declined to restrain Endo and Dr. Reddy’s and
gave Ranbaxy and the FDA until 21 November to propose a schedule for further
proceedings. A Ranbaxy representative in Gurgaon didn’t immediately respond to
an email before regular business hours seeking comment on the ruling.
complaint filed on 14 November in federal
court in Washington. Ranbaxy, based in Gurgaon, wanted the order to prevent
competitors Dr. Reddy’s Laboratories Ltd and the US unit of Dublin-based Endo
International Plc from moving ahead with marketing their generic versions of
the compounds while its complaint was heard. US district judge Beryl Howell on
Thursday declined to restrain Endo and Dr. Reddy’s and gave Ranbaxy and the FDA
until 21 November to propose a schedule for further proceedings. A Ranbaxy
representative in Gurgaon didn’t immediately respond to an email before regular
business hours seeking comment on the ruling. Bloomberg.
PRAVEEN SHARMA
PGDM 3RD SEM
COMMENT-
Ranbaxy
wanted the order to prevent competitors Dr. Reddy’s Laboratories Ltd and the US
unit of Dublin-based Endo International from moving ahead with marketing their
generic versions of the compounds while
No comments:
Post a Comment